Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (19)

2024

  1. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

    Cancer research communications, Vol. 4, Núm. 6, pp. 1609-1619

  2. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  2. Overview of virus and cancer relationships. Position paper

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555

  3. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

    European Journal of Cancer, Vol. 151, pp. 211-220

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2018

  1. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

    European Respiratory Journal

  2. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    Mayo Clinic Proceedings, Vol. 93, Núm. 3, pp. 307-320

2017

  1. A consensus statement on the gender perspective in lung cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

  2. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 568-573

2016

  1. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients

    Journal of Gynecologic Oncology, Vol. 27, Núm. 1

2015

  1. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial

    JAMA Oncology, Vol. 1, Núm. 2, pp. 149-157

  2. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

    Molecular Oncology, Vol. 9, Núm. 2, pp. 422-436

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

  2. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

  1. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation

    European Respiratory Journal, Vol. 37, Núm. 3, pp. 624-631

2000

  1. Tumor markers at the time of recurrence in patients with germ cell tumors

    Cancer, Vol. 88, Núm. 1, pp. 162-168